Dyne Therapeutics (NASDAQ:DYN) CEO John Cox Sells 2,640 Shares

Key Points

• Dyne Therapeutics CEO John Cox sold 2,640 shares at an average price of $13.41, reducing his stake to 199,539 shares valued at approximately $2.68 million.
• The company reported an earnings per share (EPS) of ($0.97) for the last quarter, exceeding analysts' expectations of ($0.99).
• Investment analysts have mixed ratings on Dyne Therapeutics, with an average rating of "Buy" and a consensus target price of $34.07.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) CEO John Cox sold 2,640 shares of the business's stock in a transaction on Friday, September 5th. The stock was sold at an average price of $13.41, for a total value of $35,402.40. Following the transaction, the chief executive officer owned 199,539 shares of the company's stock, valued at $2,675,817.99. This trade represents a 1.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

John Cox also recently made the following trade(s):

• On Monday, July 14th, John Cox purchased 100,000 shares of Dyne Therapeutics stock. The shares were acquired at an average cost of $9.11 per share, for a total transaction of $911,000.00.

Dyne Therapeutics Stock Performance

Shares of NASDAQ DYN traded down $0.05 during midday trading on Tuesday, reaching $13.25. 1,509,748 shares of the company traded hands, compared to its average volume of 2,620,778. The company has a market cap of $1.88 billion, a price-to-earnings ratio of -3.43 and a beta of 1.10. The stock has a 50-day moving average price of $10.87 and a 200 day moving average price of $11.12. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $37.08. The company has a debt-to-equity ratio of 0.17, a current ratio of 16.83 and a quick ratio of 16.83.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Monday, July 28th. The company reported ($0.97) EPS for the quarter, topping analysts' consensus estimates of ($0.99) by $0.02. Sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Sanford C. Bernstein assumed coverage on Dyne Therapeutics in a research note on Tuesday, June 24th. They set a "market perform" rating and a $13.00 price target for the company. Royal Bank Of Canada cut their price objective on Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating for the company in a report on Tuesday, July 29th. Stifel Nicolaus lowered their target price on Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating on the stock in a report on Thursday, July 31st. Robert W. Baird cut their price target on shares of Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating for the company in a report on Wednesday, June 18th. Finally, Oppenheimer reduced their price objective on shares of Dyne Therapeutics from $34.00 to $13.00 and set an "outperform" rating for the company in a research report on Wednesday, August 6th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics currently has an average rating of "Buy" and a consensus target price of $34.07.

Institutional Trading of Dyne Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Squarepoint Ops LLC raised its position in Dyne Therapeutics by 334.3% during the second quarter. Squarepoint Ops LLC now owns 181,740 shares of the company's stock valued at $1,730,000 after buying an additional 139,896 shares during the period. Thrivent Financial for Lutherans purchased a new position in Dyne Therapeutics during the 2nd quarter valued at about $420,000. Caxton Associates LLP increased its holdings in shares of Dyne Therapeutics by 10.9% in the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company's stock valued at $158,000 after purchasing an additional 1,627 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company's stock worth $100,000 after purchasing an additional 7,697 shares in the last quarter. Finally, Wasatch Advisors LP lifted its position in shares of Dyne Therapeutics by 9.2% in the second quarter. Wasatch Advisors LP now owns 557,937 shares of the company's stock worth $5,312,000 after purchasing an additional 46,889 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.